ArticleFrontiers in endocrinology2026
Impact of antenatal corticosteroid exposure on glycemic control in preterm infants assessed by continuous glucose monitoring: preliminary results from a single center study.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Antenatal corticosteroids (ACS) are routinely administered to women at risk of preterm delivery to improve neonatal respiratory outcomes. However, ACS exposure has been associated with neonatal hypoglycemia, and its impact on overall glycemic control and variability-particularly at earlier gestational ages-remains incompletely defined. Objectives: To evaluate glycemic control using continuous glucose monitoring (CGM) in preterm infants exposed to ACS and to assess the influence of timing of administration and gestational age on glycemic patterns. Methods: This prospective single-center cohort study included preterm infants born at <35 weeks of gestation and admitted to a level III neonatal intensive care unit between February 2023 and August 2024. Infants were classified according to ACS exposure as complete course, partial course, or no exposure. CGM was performed during the first 48 hours of life. Hypoglycemic (<45 mg/dL) and hyperglycemic (>180 mg/dL) events, as well as glycemic variability assessed by the mean amplitude of glycemic excursions (MAGE), were analyzed. Subgroup analyses were conducted based on the interval between ACS administration and delivery (≤7 days vs >7 days) and gestational age (<34 vs ≥34 weeks). Statistical significance was adjusted using the Benjamini-Hochberg procedure. Results: Sixty-four infants were included (41 complete ACS, 15 partial ACS, 8 no ACS). Baseline characteristics were comparable among groups. During the first day of life, hypoglycemic events occurred exclusively in infants exposed to a complete course of ACS (p = 0.005), predominantly in those exposed within seven days prior to delivery. This difference was not observed on the second day. Hyperglycemic events were significantly more frequent in infants born before 34 weeks of gestation (p = 0.005). Glycemic variability, assessed by MAGE, did not differ significantly according to ACS exposure, timing, or gestational age. Conclusions: Exposure to a complete and recent course of ACS is associated with an increased risk of early neonatal hypoglycemia in preterm infants, particularly within the first 24 hours of life. CGM enables detailed assessment of glycemic instability and may support improved metabolic monitoring in this high-risk population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.